Oak Thistle LLC Grows Stake in Zimmer Biomet Holdings, Inc. $ZBH

Oak Thistle LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 78.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,314 shares of the medical equipment provider’s stock after purchasing an additional 12,921 shares during the quarter. Oak Thistle LLC’s holdings in Zimmer Biomet were worth $2,636,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rakuten Investment Management Inc. acquired a new stake in shares of Zimmer Biomet during the third quarter worth $37,307,000. Sector Gamma AS lifted its stake in shares of Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after buying an additional 24,847 shares during the period. SG Americas Securities LLC lifted its stake in shares of Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after buying an additional 13,812 shares during the period. Border to Coast Pensions Partnership Ltd lifted its stake in shares of Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after buying an additional 22,104 shares during the period. Finally, National Pension Service lifted its position in Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after purchasing an additional 16,928 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. UBS Group restated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Robert W. Baird restated a “neutral” rating and set a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Finally, Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Trading Up 0.4%

Shares of Zimmer Biomet stock opened at $91.38 on Wednesday. The firm has a 50-day simple moving average of $92.51 and a two-hundred day simple moving average of $93.49. The company has a market cap of $17.69 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 1.86 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.